Tyra Biosciences (TYRA) Cash from Operations (2020 - 2026)

Tyra Biosciences has reported Cash from Operations for 7 years, with the latest figure at 32571000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Operations fell 27.94% year-over-year to 32571000.0; the trailing twelve-month figure through Mar 2026 stood at 102255000.0 (down 39.68% YoY), and the FY2025 full-year result was 95142000.0, down 36.36% from the prior year.
• Cash from Operations for Q1 2026 stood at 32571000.0, down from 23624000.0 in the prior quarter.
• The five-year high for Cash from Operations was 8925000.0 in Q1 2022, with the low at 32571000.0 in Q1 2026.
• Historically, Cash from Operations has averaged 17524176.47 across 5 years, with a median of 17168000.0 in 2022.
• Annual changes were most pronounced in 2022 — Cash from Operations slumped 284.85% — and 2023, when it surged 43.99%.
• Tyra Biosciences' Cash from Operations stood at 11980000.0 in 2022, then retreated by 12.95% to 13532000.0 in 2023, then tumbled by 44.77% to 19590000.0 in 2024, then slipped by 20.59% to 23624000.0 in 2025, then plunged by 37.87% to 32571000.0 in 2026.
• The last three Cash from Operations figures came in at 32571000.0 (Q1 2026), 23624000.0 (Q4 2025), and 22380000.0 (Q3 2025), per Business Quant data.